Alzheimer?s disease (AD) is the most common cause of dementia in today?s aging population, and the disease begins insidiously and silently 5-10 years before major symptoms appear (i.e., cognition impairment). However, the pathogenic mechanisms are still not fully understood, and there is no effective therapy. Neuropathological hallmarks of AD are neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau and senile plaques comprising amyloid-? peptides (A?) derived from amyloid precursor protein (APP). Interestingly, pathogenic APP processing and tau hyperphosphorylation is highly regulated by various protein kinases or phosphatases in AD. Moreover, there is a growing body of the evidence that A? deposits are associated with tau tangles. Therefore, a targeting agent that can effectively and safely ameliorate NFTs and amyloid plaques represent promising therapeutic and potential prophylactic treatments in neurodegenerative conditions including AD. In our parent R01 project NIBIB #R01EB022230, we have been developing multifunctional nanoprobes which enable targeting, imaging, and image-guided intervention of pancreatic neuroendocrine tumors (PNETs). Briefly, by engineering chemical moieties composing nanoprobes systematically, we were able deliver nanoprobes to the pancreas and achieve selective targeting of PNETs. Moreover, over 80% of the injected dose was ultimately eliminated into urine within 24 h. This narrows the chemical window to be modulated among targeting anchor, imaging moiety, and distribution domain; however, our laboratory has worked diligently to create a reciprocal arrangement whereby each chemical composition provides balancing properties to the others. Interestingly, during the evaluation of the cellular mechanism and biodistribution of the targeted nanoprobes, we found some pancreas-targeted contrast agents show great affinities in the brain tissue, specifically to the A? peptides, which is structurally similar to the death-associated protein kinase 1 (DAPK1) inhibitor. DAPK1 promotes tau protein accumulation and its phosphorylation. Moreover, DAPK1 ablation in mice decreases tau protein stability and its phosphorylation at multiple AD-related sites. Originally identified as an important positive mediator of neuronal cell death, DAPK1 kinase activity-deficient mice are more efficient learners and have better spatial memory than wild type mice and DAPK1 is also genetically linked to late onset AD. These results suggest that aberrant DAPK1 activation might contribute to age-dependent neurodegeneration including AD. Our hypothesis guiding this study is that nanoprobes composed of DAPK1 inhibitors and targeting modulators (nanoinhibitors) can be an effective tool for accurate diagnosis of AD in its early state and their prognostic treatment. We propose to test DAPK1 inhibiting nanoprobes for biodistribution and pharmacokinetics using AD mouse models, as the lead compound in this proof of concept application. Thus, the overall goal in this supplemental application is to develop ultrasmall nanoinhibitors that are complexed with inhibitors targeted to both A? and tau, and evaluate the functionality and targetability in AD animal models.

Public Health Relevance

Alzheimer?s disease (AD) and related neurodegenerative dementias are characterized by a progressive loss of memory. Neuropathological hallmarks of AD are neurofibrillary tangles composed of hyperphosphorylated tau and senile plaques comprising amyloid-? peptides. Using ultrasmall nanoparticles, we propose to deliver targeted inhibitors to amyloid-? and tau in AD, which will lead to new strategies for delivering AD-targeted therapeutics to the brain using ultrasmall zwitterionic nanoprobes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Biomedical Imaging and Bioengineering (NIBIB)
Type
Research Project (R01)
Project #
3R01EB022230-03S1
Application #
9879188
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Atanasijevic, Tatjana
Project Start
2017-09-16
Project End
2021-05-31
Budget Start
2019-09-19
Budget End
2020-05-31
Support Year
3
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02114
Levitz, Andrew; Marmarchi, Fahad; Henary, Maged (2018) Introduction of various substitutions to the methine bridge of heptamethine cyanine dyes Via substituted dianil linkers. Photochem Photobiol Sci 17:1409-1416
Hu, Shuang; Kang, Homan; Baek, Yoonji et al. (2018) Real-Time Imaging of Brain Tumor for Image-Guided Surgery. Adv Healthc Mater 7:e1800066
Levitz, Andrew; Marmarchi, Fahad; Henary, Maged (2018) Synthesis and Optical Properties of Near-Infrared meso-Phenyl-Substituted Symmetric Heptamethine Cyanine Dyes. Molecules 23:
Wada, Hideyuki; Hyun, Hoon; Bao, Kai et al. (2018) Multivalent Mannose-Decorated NIR Nanoprobes for Targeting Pan Lymph Nodes. Chem Eng J 340:51-57